Kinathera
Entity

  • Kinathera

    Created in 2015


  • Up & running (A)
    Existing signals show a regular activity

  • Social networks

    886

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    163 Av. de Luminy, 13009 Marseille, France

    Marseille

    France

  • Employees

    Scale: 2-10

    Estimated: 3

  • Engaged corporates

    2
    2 0

  • Added in Motherbase

    1 month, 3 weeks ago
Description
  • Value proposition

    develop first-in-class oral drugs for autoimmune diseases.

    Kinathera is a seed stage preclinical biotech on a mission to develop unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders.
    Selective inhibition of our most advanced target, simultaneously:
    1, blocks intracellular cascade of the ICOS receptor which control maturation of the humoral response and
    2, inhibits type 1 interferon production, a master regulator of BAFF expression and demonstrated component of auto-immune diseases.
    Activity of Kinathera’s compound on two key immune paths promises enhanced control of hyperactive immune reaction in auto immune or GvHD indications.

    Organ Transplantation, Drug Development, Acute Kidney Injury (AKI), Autoimmune, Sjoegren's syndrome, Dermatomyositis, Systemic scleroderma, Interferonopathies, and GvHD

  • Original language

    develop first-in-class oral drugs for autoimmune diseases.

    Kinathera is a seed stage preclinical biotech on a mission to develop unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders.
    Selective inhibition of our most advanced target, simultaneously:
    1, blocks intracellular cascade of the ICOS receptor which control maturation of the humoral response and
    2, inhibits type 1 interferon production, a master regulator of BAFF expression and demonstrated component of auto-immune diseases.
    Activity of Kinathera’s compound on two key immune paths promises enhanced control of hyperactive immune reaction in auto immune or GvHD indications.

Corporate interactions
Corporate TypeTweets Articles
Grand Luminy Technopole
Grand Luminy Technopole
Business Consulting and Services
Grand Luminy Technopole
Business Consulting and Services 		Other

31 Oct 2023


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research 		Other

18 Jan 2024


Similar entities
Last news
Show all articles
Social network dynamics